CEBPB and Itraconazole Synergistically Suppress Esophageal Squamous Cell Carcinoma Growth and Overcome Cisplatin Drug Resistance

Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is a predominant subtype of esophageal cancer in East Asia and is associated with high cancer-related mortality. CCAAT/enhancer-binding protein beta (CEBPB) is implicated in tumor progression and chemoresistance; however, its functional role and therapeutic potential in ESCC remain poorly understood. This study aimed to investigate the role of CEBPB in ESCC progression and cisplatin resistance and to explore its potential as a therapeutic target. Methods: CEBPB expression and its clinical significance were evaluated using public datasets and human ESCC tissue arrays. A human reflux model, esophageal organoids, and ESCC cell lines were used to investigate the effects of CEBPB on epithelial proliferation, differentiation, and cisplatin sensitivity. CEBPB gain- and loss-of-function experiments, apoptosis assays, pathway gene profiling and luciferase reporter assays were performed to assess its biological functions and transcriptional activity. The effects of combined cisplatin and itraconazole treatment were evaluated in ESCC cells. Statistical analyses were performed using unpaired t-tests or one-way ANOVA, and survival was analyzed using the Kaplan–Meier method and log-rank test. Results: In non-neoplastic esophageal tissues, increased CEBPB expression was associated with reflux-induced basal cell hyperplasia. Organoid experiments demonstrated that CEBPB promoted cell proliferation while suppressing basal cell differentiation. CEBPB expression was significantly elevated during ESCC progression, and higher expression was associated with poorer overall survival (P < 0.05). In cultured ESCC cells, CEBPB enhanced cell growth and survival by directly regulating the transcription of the anti-apoptotic gene MCL1. Elevated CEBPB expression conferred resistance to cisplatin, whereas CEBPB knockdown increased apoptosis and reduced MCL1 expression in cisplatin-resistant ESCC cells. Furthermore, combined treatment with cisplatin and itraconazole promoted apoptosis in cisplatin resistant and naïve ESCC cells compared with cisplatin treatment alone. Conclusions: CEBPB promotes ESCC progression and contributes to cisplatin resistance, at least in part, through transcriptional regulation of MCL1. Targeting CEBPB in combination with cisplatin may represent a potential therapeutic strategy for overcoming chemoresistance in ESCC and may have broader relevance across multiple cancer types in which CEBPB contributes to disease progression and drug resistance.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1835.v1
Primary Topic
Esophageal Cancer Research and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CEBPB and Itraconazole Synergistically Suppress Esophageal Squamous Cell Carcinoma Growth and Overcome Cisplatin Drug Resistance

Ji Li, Pi Liu, Wei Zhang, Qiuyang Zhang
Preprints.org
Esophageal Cancer Research and Treatment
preprint

CEBPB and Itraconazole Synergistically Suppress Esophageal Squamous Cell Carcinoma Growth and Overcome Cisplatin Drug Resistance

Ji Li, Pi Liu, Wei Zhang, Qiuyang Zhang
preprint en

Abstract

Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is a predominant subtype of esophageal cancer in East Asia and is associated with high cancer-related mortality. CCAAT/enhancer-binding protein beta (CEBPB) is implicated in tumor progression and chemoresistance; however, its functional role and therapeutic potential in ESCC remain poorly understood. This study aimed to investigate the role of CEBPB in ESCC progression and cisplatin resistance and to explore its potential as a therapeutic target. Methods: CEBPB expression and its clinical significance were evaluated using public datasets and human ESCC tissue arrays. A human reflux model, esophageal organoids, and ESCC cell lines were used to investigate the effects of CEBPB on epithelial proliferation, differentiation, and cisplatin sensitivity. CEBPB gain- and loss-of-function experiments, apoptosis assays, pathway gene profiling and luciferase reporter assays were performed to assess its biological functions and transcriptional activity. The effects of combined cisplatin and itraconazole treatment were evaluated in ESCC cells. Statistical analyses were performed using unpaired t-tests or one-way ANOVA, and survival was analyzed using the Kaplan–Meier method and log-rank test. Results: In non-neoplastic esophageal tissues, increased CEBPB expression was associated with reflux-induced basal cell hyperplasia. Organoid experiments demonstrated that CEBPB promoted cell proliferation while suppressing basal cell differentiation. CEBPB expression was significantly elevated during ESCC progression, and higher expression was associated with poorer overall survival (P < 0.05). In cultured ESCC cells, CEBPB enhanced cell growth and survival by directly regulating the transcription of the anti-apoptotic gene MCL1. Elevated CEBPB expression conferred resistance to cisplatin, whereas CEBPB knockdown increased apoptosis and reduced MCL1 expression in cisplatin-resistant ESCC cells. Furthermore, combined treatment with cisplatin and itraconazole promoted apoptosis in cisplatin resistant and naïve ESCC cells compared with cisplatin treatment alone. Conclusions: CEBPB promotes ESCC progression and contributes to cisplatin resistance, at least in part, through transcriptional regulation of MCL1. Targeting CEBPB in combination with cisplatin may represent a potential therapeutic strategy for overcoming chemoresistance in ESCC and may have broader relevance across multiple cancer types in which CEBPB contributes to disease progression and drug resistance.

Preprints.org
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon